LGG Probiotic for Antibiotic-Associated Diarrhea: What the Research Shows

Antibiotic-associated diarrhea (AAD) affects between 5% and 39% of patients taking antibiotics, depending on the antibiotic type and individual factors. It happens because antibiotics disrupt the balance of gut bacteria, allowing opportunistic organisms to flourish. Lactobacillus rhamnosus GG (LGG) is the single most studied probiotic strain for preventing this specific problem.

What Is Antibiotic-Associated Diarrhea?

AAD occurs when antibiotics kill beneficial gut bacteria along with the targeted pathogens. This disruption can cause symptoms ranging from mild loose stools to severe, watery diarrhea. The most concerning form involves Clostridioides difficile (C. diff) infection, which can cause serious complications.

Common antibiotics associated with AAD include amoxicillin, amoxicillin-clavulanate, cephalosporins, and clindamycin. Broad-spectrum antibiotics carry the highest risk because they affect the widest range of gut bacteria.

Why LGG Specifically?

Not all probiotic strains are equal when it comes to AAD prevention. LGG (ATCC 53103) has specific properties that make it particularly relevant:

• Acid and bile resistance: LGG survives passage through the stomach and reaches the intestines alive (Goldin et al., 1992).
• Mucus adhesion: LGG adheres to intestinal mucus more effectively than most other Lactobacillus strains, allowing it to colonize temporarily during and after antibiotic treatment (Alander et al., 1999).
• Pathogen inhibition: LGG produces substances that inhibit the growth of several harmful bacteria, including some strains of C. difficile (Silva et al., 1987).
• Immune modulation: LGG stimulates the production of secretory IgA in the gut, which supports the mucosal immune barrier (Kaila et al., 1992).

What the Clinical Trials Show

Meta-Analyses and Systematic Reviews

The strongest evidence for LGG and AAD prevention comes from meta-analyses that pool results across multiple trials:

• Goldenberg et al. (2017, Cochrane Review): A comprehensive Cochrane systematic review of probiotics for C. difficile-associated diarrhea found that probiotics, with LGG among the most frequently studied strains, significantly reduced the risk of C. difficile-associated diarrhea by about 60% in patients receiving antibiotics. The review included 31 randomized controlled trials with over 8,000 participants.
• Szajewska and Kolodziej (2015): A systematic review focused specifically on LGG for preventing AAD analyzed 12 randomized controlled trials with 1,499 participants. The pooled results showed LGG reduced the risk of AAD from 22.4% to 12.3%, a relative risk reduction of 49%. The number needed to treat was 10, meaning for every 10 patients given LGG alongside antibiotics, one case of diarrhea was prevented.
• Hempel et al. (2012, JAMA): A broad meta-analysis of 63 RCTs involving 11,811 participants found that probiotic use was associated with a 42% reduction in AAD risk. LGG was identified as one of the strains with the strongest individual evidence.

Key Individual Trials

• Arvola et al. (1999): In a double-blind, placebo-controlled trial with 119 children receiving antibiotics, LGG supplementation reduced the incidence of diarrhea from 16% in the placebo group to 5% in the LGG group.
• Vanderhoof et al. (1999): A randomized trial of 188 children found that LGG given alongside antibiotics reduced the incidence of antibiotic-associated diarrhea from 26% to 8%.
• Armuzzi et al. (2001): In adults receiving H. pylori eradication therapy (a triple antibiotic regimen), LGG supplementation significantly reduced the incidence and severity of treatment-related diarrhea and other GI side effects.

Dosage Used in AAD Research

The dosages that showed results in clinical trials typically ranged from 10 billion to 20 billion CFU per day, given throughout the antibiotic course and for 1 to 2 weeks after completion. Some studies used doses as low as 1 billion CFU in pediatric populations and still observed benefits.

Most researchers recommend starting the probiotic on the first day of antibiotic treatment, taken at least 2 hours apart from the antibiotic dose. The spacing is important because taking them simultaneously may reduce the viability of the probiotic bacteria.

LGG vs Other Probiotic Strains for AAD

Several probiotic strains have been studied for AAD, but LGG has the most consistent evidence for this specific application:

• Saccharomyces boulardii: A probiotic yeast with strong evidence for AAD and C. diff prevention. Because it is a yeast rather than bacteria, it is inherently resistant to antibiotics. Some clinicians recommend it alongside bacterial probiotics.
• Lactobacillus acidophilus: Has some evidence for AAD but fewer strain-specific trials than LGG.
• Multi-strain blends: Some studies use combinations, but it is difficult to attribute results to specific strains in multi-strain products.

LGG and S. boulardii are the two strains with the strongest individual evidence for AAD prevention.

When LGG May Not Be Enough

LGG is not a treatment for active C. difficile infection. If you develop severe, persistent, or bloody diarrhea during antibiotic treatment, medical evaluation is essential. LGG research supports its use as a preventive measure alongside antibiotics, not as a replacement for medical treatment of established infections.

Individuals who are immunocompromised should consult their healthcare provider before taking any probiotic, as there have been rare case reports of Lactobacillus bacteremia in severely immunocompromised patients.

Practical Recommendations Based on the Evidence

1. Start early: Begin taking LGG on the first day of your antibiotic course.
2. Space the doses: Take LGG at least 2 hours before or after your antibiotic.
3. Continue after: Keep taking LGG for at least 1 to 2 weeks after completing antibiotics to support gut microbiome recovery.
4. Check the CFU count: Look for products providing at least 10 billion CFU per serving of LGG specifically, not a blend where LGG is a minor component.
5. Verify the strain: True LGG is Lactobacillus rhamnosus GG (ATCC 53103). Generic "L. rhamnosus" without the GG designation is a different strain with different research backing.

The Bottom Line

Antibiotic-associated diarrhea is common and disruptive. LGG has the most robust clinical evidence of any bacterial probiotic strain for preventing it. Multiple meta-analyses confirm a meaningful reduction in AAD risk when LGG is taken alongside antibiotics. The key is choosing a product with verified LGG at an adequate dose and timing it properly with your antibiotic regimen.

References:

• Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095.
• Szajewska H, Kolodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157.
• Hempel S, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-1969.
• Arvola T, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections. Pediatrics. 1999;104(5):e64.
• Vanderhoof JA, et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135(5):564-568.
• Armuzzi A, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy. Digestion. 2001;63(1):1-7.
• Goldin BR, et al. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992;37(1):121-128.
• Alander M, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG. Appl Environ Microbiol. 1999;65(1):351-354.
• Kaila M, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res. 1992;32(2):141-144.
• Silva M, et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother. 1987;31(8):1231-1233.